Cargando…
A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy
β-(1,3)/(1,6) D-glucan, a component of the fungal cell wall, has been shown to stimulate the immune system, enhance hematopoiesis, amplify killing of opsonized tumor cells and increase neutrophil chemotaxis and adhesion. In view of these attributes, the β-glucans should be studied for both their the...
Autor principal: | Weitberg, Alan B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570358/ https://www.ncbi.nlm.nih.gov/pubmed/18803849 http://dx.doi.org/10.1186/1756-9966-27-40 |
Ejemplares similares
-
Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan
por: Stier, Heike, et al.
Publicado: (2014) -
Immune modulation by non-digestible and non-absorbable beta-1,3/1,6-glucan
por: Raa, Jan
Publicado: (2015) -
Ganoderma lucidum beta 1,3/1,6 glucan as an immunomodulator in inflammation induced by a high-cholesterol diet
por: Wu, Yu-Sheng, et al.
Publicado: (2016) -
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
por: Thomas, M., et al.
Publicado: (2017) -
Beta-D-Glucan in Patients with Haematological Malignancies
por: Mikulska, Malgorzata, et al.
Publicado: (2021)